Global News

PureTech Health appoints Atul Pande chief medical officer

Friday, February 24, 2017

PureTech Health, a cross-disciplinary biopharmaceutical company, has announced the appointment of Atul Pande, M.D., as the company’s chief medical officer. In this new role, Dr. Pande will oversee all clinical operations across PureTech Health’s pipeline and work closely with the team to de-risk and advance opportunities that hold the most potential for patients.

[Read More]

NIH respiratory syncytial virus vaccine enters clinical testing

Friday, February 24, 2017

A phase I clinical trial to test the safety and tolerability of an investigational vaccine against respiratory syncytial virus (RSV) has begun at the NIH Clinical Center in Bethesda, Maryland. The trial will also assess the vaccine’s ability to prompt an immune response in healthy adult participants. The investigational vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH.

[Read More]

Northwell Health, GE Ventures partner on bioelectronic medicine

Thursday, February 23, 2017

Northwell Health‘s Feinstein Institute for Medical Research has announced a strategic alliance with GE Ventures to support the Feinstein’s Center for Bioelectronic Medicine (CBEM). With this investment, the Feinstein Institute will continue its work in discovering, developing and commercializing new diagnostic and therapeutic solutions in bioelectronic medicine for a wide range of acute and chronic diseases and injuries, including neurodegenerative diseases, cancer, diabetes and hypertension.      

[Read More]

INC Research adds investigator payment offering

Thursday, February 23, 2017

INC Research, a global phase I to IV CRO, has announced expansion of its Functional Service Provider (FSP) service offering to include investigator payment processing, leveraging the company’s extensive expertise and delivery of customized solutions in this area as well as insights gained from its industry-recognized site relationships. The addition of investigator payment processing to the company’s FSP offering builds on its nearly 20 years of experience in meeting the needs of biopharmaceutical customers worldwide for standalone outsourced services under an FSP model, including Data Management, Medical Writing, Safety and Pharmacovigilance, and Site Contracts.

[Read More]

FDA accepts Ocular’s NDA resubmission for DEXTENZA

Wednesday, February 22, 2017

Ocular Therapeutix, a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, has announced that the company’s New Drug Application (NDA) resubmission for DEXTENZA (dexamethasone insert) 0.4mg for intracanalicular use, for the treatment of ocular pain occurring after ophthalmic surgery has been accepted as a filing for review by the FDA. DEXTENZA is a product candidate administered by a physician as a bioresorbable intracanalicular insert and designed for drug release to the ocular surface for up to 30 days.

[Read More]